Real-world practitioner perceptions of CARTITUDE-4 results for patients with previously treated multiple myeloma.

ABSTRACT:

Introduction

Initially approved for the fifth-line or later therapeutic setting, the chimeric antigen receptor (CAR) T-cell regimen ciltacabtagene autoleucel (cilta-cel) was recently approved for second-line (2L) treatment in relapsed/refractory multiple myeloma (RRMM). Oncology practitioners use clinical trials to inform treatment, but real-world impressions and impact on practice are lacking. We aimed to determine whether presenting CARTITUDE-4 clinical trial data would impact real-world preferences/perceptions around CAR T-cell therapy.

Methods

Recruiting from the Cardinal Health Oncology Provider Extended Network (OPEN), we surveyed hematologists/oncologists to investigate fourth-line (4L) preferences in a hypothetical patient with triple-class-refractory MM. We posed th

SUBMITTER: Balanean A 

PROVIDER: S-EPMC11647711 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature